학술논문
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
Document Type
Article
Author
Madhi, Shabir A ; Moodley, Dhayendre; Hanley, Sherika; Archary, Moherndran; Hoosain, Zaheer; Lalloo, Umesh; Louw, Cheryl; Fairlie, Lee; Fouche, Leon Frederik; Masilela, Mduduzi S L; Singh, Nishanta; Grobbelaar, Coert; Ahmed, Khatija; Benadé, Gabriella; Bhikha, Sutika; Bhorat, As'ad Ebrahim; Bhorat, Qasim; Joseph, Natasha; Dheda, Keertan; Esmail, Aliasgar; Foulkes, Sharne; Goga, Ameena; Oommen Jose, Aylin; Kruger, Gertruida; Kalonji, Dishiki J; Lalloo, Natasha; Lombaard, Johan J; Lombard Koen, Anthonet; Kany Luabeya, Angelique; Mngqibisa, Rosie; Petrick, Friedrich G; Pitsi, Annah; Tameris, Michele; Thombrayil, Asha; Vollgraaff, Pieter-Louis; Cloney-Clark, Shane; Zhu, Mingzhu; Bennett, Chijioke; Albert, Gary; Faust, Emmanuel; Plested, Joyce S; Fries, Lou; Robertson, Andreana; Neal, Susan; Cho, Iksung; Glenn, Greg M; Shinde, Vivek
Source
In The Lancet HIV May 2022 9(5):e309-e322
Subject
Language
ISSN
2352-3018